Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Lurasidone Hydrochloride). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Lura-120 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Lurasidone should be taken with food, providing at least 350 calories, since taking it with food substantially increases how well it is absorbed. For schizophrenia, the recommended starting dose is 40 mg once daily, and no initial dose titration is required. The maximum recommended dose is 160 mg per day. For depressive episodes associated with Bipolar I Disorder, the recommended starting dose is 20 mg once daily, whether used alone or as an add on therapy with lithium or valproate, and no initial dose titration is required. The maximum recommended dose, whether used alone or as an add on therapy with lithium or valproate, is 120 mg per day. In moderate to severe renal impairment, the recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day. In moderate to severe hepatic impairment, the recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day for moderate hepatic impairment and 40 mg per day for severe hepatic impairment. Safety and effectiveness in pediatric patients have not been established.
Side Effects
Common side effects include drowsiness, restlessness (akathisia), movement-related symptoms such as tremor or stiffness (extrapyramidal symptoms), and nausea.
Cautions & Contraindications
Warnings & Precautions
Cerebrovascular reactions in elderly patients with dementia-related psychosis: There is a higher chance of cerebrovascular events such as stroke or transient ischemic attack in this group. Neuroleptic malignant syndrome: Stop the medicine right away and monitor the patient closely if this develops. Tardive dyskinesia: Discontinue treatment if it becomes clinically appropriate to do so. Metabolic changes: Atypical antipsychotic drugs, including this one, have been linked to metabolic changes that can raise cardiovascular and cerebrovascular risk. These changes include high blood sugar, dyslipidemia, and weight gain. Hyperglycemia and diabetes mellitus: Watch for signs of high blood sugar such as excessive thirst, frequent urination, increased hunger, and weakness. Check blood glucose regularly in patients who have diabetes or are at risk of it. Dyslipidemia: Unwanted changes in blood lipid levels have been seen in patients taking atypical antipsychotics. Weight gain: Patients may gain body weight while on treatment, so weight should be monitored. Hyperprolactinemia: Blood prolactin levels may rise during treatment. Leukopenia, neutropenia, and agranulocytosis: A complete blood count (CBC) should be done in patients who already have a low white blood cell (WBC) count or a history of leukopenia or neutropenia. If the white blood cell count drops significantly for no other clear reason, stopping Lurasid should be considered. Orthostatic hypotension and syncope: Dizziness, a fast or slow heart rate, and fainting can occur, particularly early in treatment. In patients with known cardiovascular or cerebrovascular disease, and in those who have not taken antipsychotics before, a lower starting dose with slower dose increases should be considered.
Contraindications
Do not use lurasidone if any of the following apply: known hypersensitivity to it; you are currently taking a strong CYP3A4 inhibitor (such as ketoconazole); you are currently taking a strong CYP3A4 inducer (such as rifampin); or the condition being treated is psychosis related to dementia.